Bleeding Disorders Treatment Market Analysis
Bleeding Disorders Treatment Market – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026
A bleeding disorder is a state in which the normal clotting function of blood is adversely affected. On an injury to the body, blood normally starts to clot to prevent major loss of blood. Occasionally, certain situations prevent blood from clotting properly, which can result in heavy or prolonged bleeding. Bleeding disorders can cause abnormal bleeding both outside and inside of the body. Some disorders can drastically increase the amount of blood lost by the body. Others cause bleeding to follow under the skin or in vigorous organs, such as the brain. Normal blood clotting involves blood components called ‘platelets’ and as many as there are 20 different plasma proteins in body called as blood clotting or coagulation factors. These factors interact with other chemicals to form a substance called fibrin which stops bleeding. Complications can occur when certain factors are low or missing in body. Bleeding problems can range from mild to severe. Some bleeding disorders are present at time of birth and some are passed through families (inherited).
According to American Society of Hematology, in 2016, around 20,000 people in the U.S. suffer from hemophilia, a condition that is predominantly observed in males. Hemophilia is the most well-known inherited bleeding disorder, although it is rather rare. On the other hand, many people are affected by von Willebrand disease, the most common inherited bleeding disorder in the U.S. caused by clotting proteins. This disease can affect both males and females and is found in nearly 1% of the U.S. population. And according to the Centers for Disease Control and Prevention (CDC) statistics, in the U.S. around 400 newborns suffer from hemophilia every year.
Generic products to be the growth factor for bleeding disorders treatment market
The bleeding disorder treatment market is driven by the large customer base, growing awareness about the bleeding disorders and available cures, and favorable compensation policies. Patent expiry of existing brands will also provide generic drug manufacturers opportunities to enter the lucrative bleeding disorder therapeutics market. Market for bleeding disorder treatment is mostly focused towards western countries of North America and Europe, owing to the high price of branded drugs. Low cost drugs will help in market penetration in under developed and developing countries, where patients cannot afford high cost of medical treatment. Hence, availability of cheap generic drugs will boost market growth in the countries of Middle East and Africa, Asia-Pacific (APAC), and Latin America.
North America is estimated to contribute the largest share of the market throughout the forecast period. The market in APAC is estimated to register the highest growth during the forecast period, owing to increasing awareness of these disorders in the emerging economies such as India and China.
The global bleeding disorder treatment market is highly competitive in nature. Technological advances will expand the boundaries of the market by adding new products such as Shire launched Vonvendi in the U.S. (In 2016), bringing the first recombinant von Willebrand factor treatment to market eight months after winning approval from the Food and Drug Administration(FDA). Key players operating in the global bleeding disorders treatment market are Bayer Healthcare, Biogen Idec, Novo Nordisk, Xenetic Biosciences, Shire, Sanofi, Cangene Corporation, CSL Behring, Alnylam Pharmaceuticals, Pfizer, Inc., Novo Nordisk, Amgen, Inc., Janssen Pharmaceuticals, and Octapharma.
Bleeding Disorders Treatment Market Taxonomy
By Type of Disorder,
By Drug Class